Your browser doesn't support javascript.
loading
Current progress in microRNA profiling of circulating extracellular vesicles in amyotrophic lateral sclerosis: A systematic review.
Ueno, Yuji; Morishima, Yuto; Hata, Takanori; Shindo, Atsuhiko; Murata, Hiroaki; Saito, Tatsuya; Nakamura, Yuki; Shindo, Kazumasa.
Afiliação
  • Ueno Y; Department of Neurology, University of Yamanashi, Chuo, Japan. Electronic address: uenoy@yamanashi.ac.jp.
  • Morishima Y; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Hata T; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Shindo A; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Murata H; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Saito T; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Nakamura Y; Department of Neurology, University of Yamanashi, Chuo, Japan.
  • Shindo K; Department of Neurology, University of Yamanashi, Chuo, Japan.
Neurobiol Dis ; 200: 106639, 2024 Oct 01.
Article em En | MEDLINE | ID: mdl-39168358
ABSTRACT

INTRODUCTION:

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease affecting upper and lower motor neurons, leading to death resulting mainly from respiratory failure, for which there is currently no curative treatment. Underlying pathological mechanisms for the development of ALS are diverse and have yet to be elucidated. Non-invasive testing to isolate circulating molecules including microRNA to diagnose ALS has been reported, but circulating extracellular vesicle (EV)-derived microRNA has not been fully studied in the ALS population.

METHODS:

A systematic literature review to explore studies investigating the profile of microRNAs in EVs from blood samples of ALS patients was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline.

RESULTS:

Eleven studies including a total of 263 patients with ALS were included in the present systematic review. The majority of patients had sporadic ALS, though a small number of patients with ALS having genetic mutations were included. Seven studies used plasma-derived EVs, and the remaining four studies used serum-derived EVs. RNA sequencing or microarrays were used in eight studies, and quantitative PCR was used in eight studies, of which five studies used RNA sequencing or microarrays for screening and quantitative PCR for validation. There was overlap of miR-199a-3p and miR-199a-5p in three studies.

CONCLUSIONS:

Overall, the systematic review addressed the current advances in the profiling of microRNAs in circulating EVs of ALS patients. Blood samples, isolation of EVs, and microRNA analysis were diverse. Although there was an overlap of miR-199a-3p and miR-199a-5p, collection of further evidence is warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Vesículas Extracelulares / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Vesículas Extracelulares / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2024 Tipo de documento: Article